Claims
- 1. A pharmaceutically active pyrrolo-p-carboline derivative represented by formula (II):
- 2. A compound according to claim 1 having a structure according to formula V:
- 3. A compound according to claim 1 having a structure according to formula VI:
- 4. A pharmaceutically active pyrrolo-carboline derivative represented by formula (I):
- 5. The pharmaceutically active pyrrolo-β-carboline derivative of claim 4 wherein X5 is N.
- 6. A compound according to claim 4 having a structure according to formula IV:
- 7. A pharmaceutically active 3-(indol-3-yl)-1H-pyrrole-2,5-dione, represented by formula III:
- 8. A compound according to claim 7 having a structure according to formula VII:
- 9. A compound having a structure according to formula 109, 110 or 111:
- 10. A method of treatment or prevention of a condition selected from the group consisting of neurodegenerative diseases, both of the central and peripheral nervous systems, inflammatory diseases, conditions resulting in loss of growth and cellular differentiation control, and cancer by administration of an effective amount of a compound according to claim 1 to a patient in need thereof.
- 11. The method of treatment according to claim 10, wherein said compound is combined with an anti-neoplastic, an anti-neurotoxic, an anti-depressant or an antisense compound.
- 12. A method of treatment or prevention of a condition selected from the group consisting of neurodegenerative diseases, both of the central and peripheral nervous systems, inflammatory diseases, conditions resulting in loss of growth, re-growth, and cellular differentiation control by administration of an effective amount of a compound according to claim 4 to a patient in need thereof.
- 13. The method of treatment according to claim 12, wherein said compound is combined with an anti-neoplastic, an anti-neurotoxic, an anti-depressant or an antisense compound.
- 14. A method of treatment or prevention of a condition selected from the group consisting of neurodegenerative diseases, both of the central and peripheral nervous systems, inflammatory diseases, conditions resulting in loss of growth, re-growth, and cellular differentiation control by administration of an effective amount of a compound according to claim 7 to a patient in need thereof.
- 15. The method of treatment according to claim 14, wherein said compound is combined with an anti-neurotoxic, an anti-depressant or an antisense compound.
- 16. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable carrier.
- 17. The pharmaceutical composition according to claim 16, additionally comprising an anti-neoplastic, an anti-neurotoxic, an anti-depressant or an antisense compound.
- 18. A pharmaceutical composition comprising a pharmaceutically effective amount of a pharmaceutically active pyrrolo-β-carboline derivative according to claim 4 in combination with a pharmaceutically acceptable carrier.
- 19. The pharmaceutical composition according to claim 18, additionally comprising an anti-neoplastic, an anti-neurotoxic, an anti-depressant or an antisense compound.
- 20. A pharmaceutical composition comprising a pharmaceutically effective amount of a pharmaceutically active 3-(indol-3-yl)-1H-pyrrole-2,5-dione according to claim 7 in combination with a pharmaceutically acceptable carrier.
- 21. The pharmaceutical composition according to claim 20, additionally comprising an anti-neoplastic, an anti-neurotoxic, an anti-depressant or an antisense compound.
- 22. A method of treating a neurodegenerative disease comprising administering to a subject in need thereof, a pharmaceutically active pyrrolo-β-carboline derivative represented by formula (I) or (II):
- 23. A method of treatment or prevention of cancer, said method comprising administration of an effective amount of a compound according to claim 4 to a patient in need thereof.
- 24. The method of treatment according to claim 23, wherein said compound is combined with an anti-neoplastic, an anti-depressant or an antisense compound.
- 25. A method of treatment or prevention of cancer, said method comprising administration of an effective amount of a compound according to claim 7 to a patient in need thereof.
- 26. The method of treatment according to claim 25, wherein said compound is combined with an anti-neoplastic an anti-depressant or an antisense compound.
Priority Claims (2)
Number |
Date |
Country |
Kind |
2,308,994 |
May 2000 |
CA |
|
PCT/CA01/00718 |
May 2001 |
WO |
|
Parent Case Info
[0001] This application is a continuation-in-part of and claims priority to U.S. patent application Ser. No. 10/276,803 (filed May 18, 2001), the entirety of which is herein incorporated by reference. U.S. patent application Ser. No. 10/276,803 is the National Phase application of PCT/CA01/00718 (filed May 18, 2001), the entirety of which is herein incorporated by reference. This application claims priority to Canadian Patent Application Serial No. 2,308,994 (Filed May 19, 2000), the entirety of which is herein incorporated by reference.